initi
cardiac
viral
infect
document
clinic
context
acut
myocard
coxsackieviru
first
viru
detect
condit
adenovirus
serotyp
later
describ
common
agent
myocard
systemat
screen
patient
dilat
cardiomyopathi
recent
reveal
rather
broad
spectrum
virus
may
also
chronic
persist
human
therefor
assum
acut
cardiac
viral
infect
may
caus
acut
ill
also
chronic
heart
diseas
definit
elimin
diseas
may
progress
termin
heart
failur
requir
heart
transplant
last
therapeut
option
rna
interfer
rnai
process
posttranscript
gene
silenc
mediat
doublestrand
rna
dsrna
introduct
doublestrand
small
interf
rna
sirna
vector
express
short
hairpin
rna
shrna
alreadi
success
use
inhibit
replic
multipl
virus
vitro
vivo
includ
respiratori
hepat
c
footandmouth
diseas
human
sar
howev
effici
rnai
depend
exact
homolog
sirna
target
sequenc
singl
mismatch
suffici
abrog
silenc
mani
rna
virus
encod
polymeras
enzym
lack
proofread
abil
result
high
mutat
rate
thu
high
probabl
virus
rapidli
develop
resist
particular
sirna
viru
replic
incorpor
nucleotid
mutat
within
target
sequenc
sirna
thu
shown
hepat
c
viru
becom
resist
particular
sirna
sever
cycl
replic
incorpor
point
mutat
within
sirna
target
similar
data
report
polioviru
therefor
therapeut
target
nonvari
virusbind
receptor
suscept
cell
host
cell
molecul
directli
indirectli
involv
viru
infect
interest
altern
target
viru
one
approach
type
show
downregul
attach
receptor
dcsign
significantli
inhibit
hiv
infect
dendrit
cell
dc
prevent
transfer
infecti
particl
dc
adenovirus
type
use
car
infect
target
cell
either
viru
attach
adenovirus
viru
intern
therefor
car
repres
attract
target
inhibit
cardiac
adenoviru
infect
shown
recent
suppress
car
rnai
result
inhibit
studi
carri
cell
noncardiac
origin
chemic
synthes
sirna
use
inhibit
car
express
howev
therapeut
use
synthet
sirna
significantli
limit
rapid
degrad
target
cell
result
transient
gene
moreov
cell
cardiac
origin
difficult
transfect
chemic
synthes
sirna
even
vitro
problem
significantli
aggrav
vivo
despit
intens
effort
recent
year
system
target
organspecif
deliveri
sirna
remain
major
hurdl
vivo
applic
rnai
therefor
investig
antivir
potenti
car
gene
silenc
cell
cardiac
origin
use
newli
develop
adenovir
vector
adv
gener
shrna
murin
rat
car
shcar
shcar
treatment
cell
primari
neonat
rat
cardiomyocyt
pncm
led
almost
complet
silenc
car
gene
express
effici
inhibit
infect
cell
type
wherea
effici
inhibit
adenoviru
infect
observ
primari
cell
studi
thu
indic
cell
typespecif
respons
cellular
car
shcar
treatment
need
consid
import
determin
new
antivir
approach
vivo
investig
efficaci
car
silenc
inhibit
adenoviru
infect
cardiac
cell
gener
total
three
shrna
direct
extracellular
domain
mcar
splice
variant
figur
follow
publish
sirna
select
dna
oligonucleotid
encod
shrna
clone
express
plasmid
control
murin
rna
polymeras
iii
promotor
test
efficaci
cotransfect
cell
plasmid
togeth
plasmid
express
recombin
transfect
control
plasmid
express
irrelev
shrna
use
determin
extent
recombin
downregul
total
cellular
rna
isol
h
transfect
northern
blot
hybrid
carri
experi
show
two
shrna
highli
effici
silenc
silenc
control
shrna
affect
neither
express
figur
analyz
specif
also
test
downregul
human
car
hcar
cotransfect
plasmid
express
recombin
solubl
hcar
none
mous
carspecif
shrna
influenc
hcarmrna
express
contrast
humanspecif
shrna
effici
silenc
hcarmrna
express
figur
consid
one
mismatch
three
mismatch
compar
hcarmrna
experi
indic
high
speci
specif
select
mcarshrna
determin
optim
adv
dose
transduct
mous
cardiac
cell
first
transduc
cell
gfpexpress
marker
adv
multipl
infect
moi
moi
gfp
express
seen
cell
wherea
cytotox
effect
observ
dose
escal
result
slight
increas
transduct
rate
figur
moi
higher
cytotox
effect
becam
evid
increas
apoptot
cell
reduct
cell
growth
cell
express
cell
surfac
shown
therefor
silenc
capac
new
figur
express
aboveevalu
effici
investig
respect
express
cell
assess
amount
advgener
cell
transduc
moi
express
analyz
h
later
time
dosedepend
transcript
detect
figur
consequ
shrna
express
strong
downregul
observ
h
transduct
near
maxim
reduct
observ
moi
higher
dose
result
signific
downregul
figur
result
indic
moi
optim
transduct
dose
allow
strong
downregul
cell
although
cytotox
viral
vector
still
low
next
investig
protein
express
transduct
cell
moi
disrupt
preexist
membraneassoci
cell
trypsin
h
transduct
reseed
procedur
led
ablat
protein
cell
surfac
day
transduct
figur
b
contrast
control
cell
rapidli
reexpress
figur
two
day
treatment
cell
still
display
membraneassoci
immunoreact
figur
probabl
reflect
residu
domain
still
anchor
cell
membran
trypsin
day
transduct
immunoreact
disappear
cell
wherea
remain
perman
detect
control
cell
figur
interestingli
car
express
celltocel
contact
site
cell
suggest
observ
stabil
car
intact
monolay
determin
homophil
heterophil
car
interact
celltocel
contact
site
togeth
result
indic
treatment
effici
inhibit
de
novo
synthesi
antivir
effect
silenc
investig
respect
cellular
car
constitut
intern
receptor
purpos
first
investig
protect
efficaci
function
dose
moi
rang
use
trypsininvolv
experiment
procedur
describ
cell
infect
h
transduct
amount
newli
gener
progeni
viru
determin
day
later
viru
plaqu
assay
clearli
demonstr
replic
cell
rather
low
frequenc
cytopathogen
effect
visibl
investig
period
expect
strongest
reduct
progeni
viru
product
observ
highest
dose
moi
nevertheless
moi
still
led
signific
inhibit
replic
respect
wherea
moi
show
signific
effect
figur
investig
whether
disrupt
preexist
car
affect
infect
either
treat
cell
trypsininvolv
experiment
procedur
describ
omit
trypsin
step
transduct
titer
progeni
viru
gener
day
infect
reduc
strongli
cell
irrespect
whether
membraneassoci
car
disrupt
trypsin
figur
experi
indic
inhibit
replic
cell
high
efficaci
moreov
proteolysi
membraneassoci
car
appar
affect
infect
car
also
involv
adenoviru
infect
attach
receptor
investig
longterm
efficaci
respect
inhibit
adenoviru
infect
examin
whether
proteolysi
preexist
car
affect
adenoviru
infect
cell
transduc
versu
control
vector
moi
h
cell
either
trypsin
reseed
medium
simpli
chang
treatment
without
trypsin
cell
infect
luciferas
marker
adenoviru
moi
day
transduct
measur
luciferas
activ
h
later
reveal
persist
reduct
marker
gene
express
cell
investig
period
clearli
demonstr
carshrna
treatment
inhibit
adenoviru
uptak
cell
markedli
less
effici
inhibit
adenoviru
infect
close
similar
trypsin
nontrypsin
cell
figur
indic
proteolysi
car
affect
function
car
adenoviru
infect
cell
perman
heartderiv
cell
line
also
interest
investig
effect
car
silenc
upon
viral
infect
primari
cardiac
cell
reason
pncm
transduc
whose
shrna
sequenc
complet
match
mous
rat
car
sequenc
control
vector
adshgfp
moi
dose
nearli
pncm
transduc
adv
shown
close
similar
cell
follow
treatment
pncm
car
express
unaffect
day
transduct
becam
strongli
downregul
day
transduct
figur
consequ
delay
car
downregul
challeng
pncm
moi
result
delay
inhibit
replic
fact
signific
reduct
replic
seen
pncm
infect
day
day
treatment
degre
inhibit
strongli
depend
dose
moi
treatment
led
reduct
titer
wherea
moi
titer
reduc
day
respect
figur
similar
result
obtain
pncm
moi
infect
adenoviru
uptak
reduc
respect
day
transduct
wherea
effect
seen
day
figur
adenovirus
common
agent
acut
myocard
inflammatori
although
treatment
potenti
elimin
cardiotrop
virus
improv
heart
function
patient
myocardi
persist
viral
specif
treatment
adenoviru
infect
avail
date
respect
antivir
therapi
rnai
promis
new
technolog
therapeut
potenti
viral
infect
demonstr
multipl
vitro
vivo
despit
encourag
result
howev
sever
report
reveal
fundament
gener
problem
sirnabas
antivir
therapi
owe
requir
strict
sequencespecif
therapeut
sirna
target
mrna
even
singl
point
mutat
viral
target
sequenc
may
result
rapid
select
escap
mutant
persist
viral
studi
show
inhibit
adenoviru
infect
possibl
via
silenc
car
receptor
mean
vectorgener
carshrna
strategi
attract
altern
sirnabas
silenc
virusencod
gene
drastic
reduc
probabl
escap
mutant
contrast
previou
investig
carri
myocardi
cell
repres
actual
target
adenoviru
infect
acut
myocard
inflammatori
treatment
cell
shcar
vector
led
effici
stabl
remov
mcar
protein
cell
surfac
consequ
signific
inhibit
adenoviru
infect
cell
remark
adenoviru
intern
reduc
despit
nearcomplet
silenc
mcar
express
wherea
infect
inhibit
contrast
car
silenc
pncm
result
strong
inhibit
adenoviru
infect
respect
adenoviru
bind
cell
exclus
mediat
car
type
adenovirus
use
car
attach
cell
wherea
intern
occur
other
shown
heparan
sulfat
glycosaminoglycan
major
histocompat
complex
class
molecul
may
also
involv
bind
adenovirus
moreov
express
receptor
involv
adenoviru
infect
highli
variabl
differ
cell
type
thu
variabl
receptor
express
level
interact
adenovirus
cell
typespecif
express
altern
receptor
like
explan
failur
complet
car
silenc
achiev
effici
blockad
adenoviru
infect
cell
enhanc
efficaci
inhibit
adenoviru
infect
via
antireceptor
approach
seem
necessari
simultan
inhibit
car
coreceptor
contrast
antiadenoviru
experi
anticar
approach
effici
respect
cell
pncm
magnitud
inhibit
infect
correl
well
vectorinduc
ablat
mcar
cell
surfac
emphas
key
role
car
infect
cardiac
cell
molecular
reason
differ
anticar
treatment
adenoviru
versu
infect
may
uniqu
role
play
car
infect
induc
conform
chang
viru
capsid
essenti
entri
target
high
efficaci
shcar
vector
viru
indic
car
silenc
promis
therapeut
approach
infect
myocardium
previou
studi
shown
similar
degre
inhibit
use
sirna
direct
viral
genom
rna
rna
combin
direct
antivir
approach
prone
escap
mutant
develop
current
antireceptor
strategi
like
increas
efficaci
rnaibas
antivir
therapi
recent
shown
silenc
car
chemic
synthes
sirna
inhibit
infect
human
cell
noncardiac
howev
approach
decreas
viru
titer
markedli
less
present
studi
employ
advgener
shcar
differ
result
high
transduct
efficaci
adv
prolong
highlevel
express
shcar
bottleneck
chemic
synthes
sirna
transient
silenc
activ
day
cardiac
viral
vector
express
shrna
howev
enabl
longterm
silenc
target
gene
cell
cardiac
allow
effici
deliveri
transgen
sequenc
among
current
avail
viral
vector
pseudotyp
vector
appear
promis
cardiac
gene
therapi
allow
highli
effici
target
transduct
heart
way
simpl
intraven
car
cell
adhes
protein
mediat
intercellular
interact
compon
special
intercellular
junction
includ
epitheli
tight
neuromuscular
myocardi
intercal
found
local
exclus
celltocel
contact
site
cell
possibl
consequ
cell
membraneassoci
car
stabil
homotyp
heterotyp
intercellular
protein
interact
contrast
previou
car
silenc
attempt
use
synthet
sirna
newli
develop
viral
vector
achiev
near
complet
stabl
knockout
car
essenti
prerequisit
reveal
significantli
differ
kinet
car
protein
ablat
differ
cell
type
particular
unexpectedli
high
stabil
car
primari
cell
versu
stabl
cell
line
data
may
explain
cell
typespecif
car
protein
kinet
differenti
carmrna
stabil
carshrna
process
cellular
micrornashrna
machineri
also
need
taken
account
delay
downregul
car
follow
vectormedi
carshrna
deliveri
primari
cardiomyocyt
relev
vivo
investig
time
lag
vector
applic
car
silenc
need
consid
develop
antivir
therapi
protocol
import
concern
associ
downregul
cellular
receptor
molecul
antivir
therapi
possibl
side
effect
result
ablat
normal
cellular
function
receptor
organogenesi
car
highli
express
heart
rapidli
downregul
post
recent
publish
genom
mous
knockout
model
cardiomyocytespecif
car
delet
result
sever
cardiac
anomali
death
day
embryon
car
gene
becam
ablat
late
embryon
develop
howev
cardefici
anim
surviv
adulthood
evid
cardiac
find
suggest
car
silenc
rnai
employ
studi
well
toler
consider
period
time
viru
migrat
spread
effici
inhibit
furthermor
treatment
cell
advgener
shcar
reveal
side
effect
found
chang
cell
growth
cell
morpholog
factin
cytoskeleton
protein
express
shown
car
compon
tight
junction
may
play
perman
role
tissu
function
sever
organ
experi
examin
car
knockdown
rnai
side
effect
vivo
even
prolong
treatment
time
summari
high
efficaci
car
gene
silenc
shrna
cardiacderiv
cell
observ
wherea
cell
typedepend
result
obtain
adenoviru
contrast
previou
silenc
attempt
use
sirna
shrnaplasmid
newli
develop
shrna
vector
abl
achiev
nearli
complet
stabl
knockout
car
transcript
turn
reveal
significantli
differ
respons
cellular
car
protein
carshrna
treatment
need
consid
import
determin
new
antivir
approach
vivo
cell
line
cardiac
muscl
cell
line
establish
mous
atrial
cardiomyocyt
tumor
lineag
kind
gift
william
c
claycomb
cell
maintain
claycomb
medium
supplement
fetal
calf
serum
fc
jrh
bioscienc
lenexa
usa
penicillin
streptomycin
mm
norepinephrin
sigma
germani
mm
lglutamin
invitrogen
karlsruh
germani
hela
human
cervic
carcinoma
cell
human
embryon
kidney
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
brl
karlsruh
germani
supplement
fc
penicillinstreptomycin
pncm
gener
maintain
describ
mcarshrna
four
short
oligonucleotid
cover
antisens
loop
sens
sequenc
shrna
synthes
oligoservic
berlin
germani
target
sequenc
encompass
nucleotid
nucleotid
see
figur
forward
revers
oligo
phosphoryl
polynucleotid
kinas
new
england
biolab
frankfurt
germani
anneal
clone
hindiiibamhidigest
psilencertm
neo
ambion
austin
tx
usa
shrna
express
cassett
clone
via
ecorihindiii
yield
plasmid
gener
express
plasmid
total
rna
first
isol
cell
reversetranscrib
use
superscriptii
revers
transcriptas
invitrogen
amplifi
use
primer
pair
pcr
pwo
polymeras
roch
mannheim
germani
result
fragment
clone
vector
invitrogen
ecori
fragment
contain
excis
insert
shuttl
plasmid
gener
recombin
express
plasmid
cdna
excis
hindiiipmei
clone
via
smaihindiii
correct
plasmid
proven
sequenc
abi
genet
analyz
appli
biosystem
foster
citi
ca
usa
adenovir
shuttl
plasmid
linear
spei
ligat
long
arm
xbaidigest
adenoviru
mutant
transfect
cell
propag
result
adv
adshplbr
addit
shgfp
express
adv
adshgfp
contain
sirna
target
sequenc
direct
gfp
gener
way
adv
describ
adv
test
possibl
rca
contamin
pcr
viru
titer
determin
standard
plaqu
assay
cell
plasmid
transfect
carri
calcium
phosphat
precipit
cell
seed
sixwel
plate
densiti
cellswel
transfect
plasmidwel
hb
buffer
ph
presenc
dmem
contain
fc
h
cell
wash
three
time
phosphatebuff
solut
pb
suppli
fresh
growth
medium
total
rna
isol
trizol
reagent
invitrogen
follow
manufactur
instruct
ten
microgram
isol
rna
electrophoret
separ
formaldehyd
agaros
gel
transfer
hybond
n
nylon
membran
amersham
buckinghamshir
uk
membran
hybrid
singlestrand
ss
antisens
dna
probe
use
excis
templat
rehybrid
control
equal
dna
load
carri
ssantisens
dna
probe
use
pcr
fragment
amplifi
hela
cell
primer
pair
label
probe
dctp
pcrlike
reaction
hybrid
filter
expos
kodak
biomax
ms
film
integra
bioscienc
fernwald
germani
hybrid
signal
intens
determin
phosphoimag
fuji
film
imag
fuji
photo
film
dusseldorf
germani
determin
fraction
cell
transduc
adv
cell
seed
sixwel
plate
densiti
cellswel
h
cell
transduc
differ
moi
adenovir
gfp
marker
vector
flow
cytometri
perform
h
later
fac
calibur
cellquest
softwar
becton
dickinson
franklin
lake
nj
usa
total
rna
cell
isol
rnazol
four
microgram
rna
incub
peqgold
dnasei
peqlab
erlangen
germani
min
reaction
stop
addit
mm
ethylenediaminetetraacet
acid
edta
heat
min
rna
reversetranscrib
use
high
capac
cdna
archiv
kit
appli
biosystem
accord
manufactur
instruct
quantif
gene
express
quantit
pcr
assay
perform
mastercycl
ep
gradient
eppendorf
taqman
univers
master
mix
ung
appli
biosystem
use
standard
condit
determin
compani
amplitaqgold
activ
min
cycl
run
denatur
temperatur
annealingextens
temperatur
min
uniqu
combin
forward
revers
primer
fluoresc
mgb
probe
design
compani
use
target
gene
hprt
gapdh
housekeep
gene
respect
use
normal
cdna
correspond
ng
rna
use
per
reaction
reaction
perform
triplic
level
express
calcul
basi
pcr
cycl
number
ct
exponenti
growth
fluoresc
probe
pass
certain
threshold
valu
rel
express
determin
differ
ct
valu
target
gene
normal
rna
input
level
use
hprt
ct
valu
rel
quantif
determin
standard
calcul
percent
semiquantit
analysi
express
includ
two
step
rt
reaction
contain
total
rna
sampl
nm
rt
primer
rt
buffer
appli
biosystem
mm
dntp
multiscrib
revers
transcriptas
appli
biosystem
rnase
inhibitor
peqlab
reaction
incub
min
min
min
held
pcr
reaction
includ
rt
product
gene
amp
pcr
buffer
u
amplitaq
dna
polymeras
roch
mm
dntp
forward
primer
revers
primer
specif
reaction
incub
gene
amp
pcr
system
appli
biosystem
min
follow
cycl
min
analyz
gel
electrophoresi
altern
quantif
carri
realtim
pcr
taqman
reaction
contain
taqman
univers
pcr
master
mix
appli
biosystem
rt
product
nm
forward
primer
nm
revers
primer
sybr
green
invitrogen
reaction
incub
plate
min
follow
cycl
min
run
triplic
threshold
cycl
ct
defin
fraction
cycl
number
fluoresc
pass
fix
threshold
rel
express
calcul
formula
cell
solubil
gener
lysi
buffer
mm
tri
ph
mm
nacl
vv
triton
mm
edta
mm
boil
lysat
min
protein
separ
nupag
gel
invitrogen
denatur
reduc
condit
transfer
onto
pvdf
membran
biorad
hercul
ca
usa
subsequ
membran
incub
anticar
polyclon
antibodi
santa
cruz
biotechnolog
santa
cruz
ca
usa
h
dri
milk
secondari
antibodi
conjug
peroxidas
dako
hamburg
germani
use
dilut
detect
chemiluminesc
achiev
use
enhanc
chemiluminesc
system
amersham
bioscienc
cell
fix
ml
trisbuff
solut
tb
contain
formaldehyd
permeabil
triton
block
tb
buffer
fc
triton
cell
incub
rabbit
polyclon
antibodi
dilut
block
solut
h
extens
rins
cell
incub
biotinlabel
secondari
antibodi
dianova
hamburg
germani
dilut
h
cell
subsequ
incub
streptavidin
dianova
dilut
min
nuclei
stain
sigma
cover
fluoromount
gtm
southern
biotechnolog
birmingham
al
usa
imag
taken
use
olympu
immunofluoresc
microscop
luciferas
assay
perform
use
luciferas
report
gene
assay
kit
roch
follow
manufactur
instruct
briefli
cell
wash
twice
pb
buffer
lyse
directli
ad
cell
lysi
reagent
incub
min
room
temperatur
cell
debri
pellet
microfug
maximum
speed
supernat
transfer
tube
sarstedt
germani
luciferas
substrat
ad
luciferas
activ
immedi
measur
lumat
lb
luminomet
berthold
bad
wildbad
germani
hela
cell
cultur
sixwel
cell
cultur
plate
confluent
monolay
densiti
cellswel
incub
eagl
mem
minim
essenti
medium
vv
fc
vv
h
cell
overlaid
ml
dilut
supernat
cell
treat
three
freezethaw
cycl
releas
intracellular
viru
hela
cell
cultur
incub
min
supernat
remov
cell
overlaid
ml
agar
contain
eagl
mem
three
day
later
cell
stain
wv
neutral
red
viru
titer
determin
plaqu
count
h
stain
mean
standard
deviat
calcul
two
independ
experi
perform
duplic
test
statist
signific
student
ttest
appli
valu
p
consid
statist
signific
